Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
Observational studyHumans
- Design
- Observational study
- Subjects
- 61 qualifying respondents out of 73, from Italian AISD members; overall response rate 1.2%
- Dose used in the study
- Not applicable; a survey of prescribing practice
- Duration
- Not stated in the abstract
- What was measured
- Clinicians' ranking of outcomes for chemotherapy-induced peripheral neurotoxicity and the drugs they prescribe for prevention and treatment
What the authors reported
This survey found:
- Pain, survival, sensory and motor impairment and quality of life were ranked most important, but rankings disagreed too much to build a DOOR algorithm.
- The most prescribed preventive agents were palmitoylethanolamide, pregabalin, gabapentin and alpha lipoic acid.
- For treatment, the most prescribed agents were pregabalin, PEA, duloxetine, gabapentin and amitriptyline.
- Many of these, the authors say, lack clinical proof of efficacy for this condition.
Limits of this study
A survey of prescribing habits, not a study of PEA's effect. Small sample, 1.2% response rate and possible selection bias, as the authors state. One author reports personal fees from MSD, Merck, Amgen and GSK outside this work.
Source
PubMed 37790191 · doi:10.2147/JPR.S414389
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.